Birth Outcomes In Eswatini After Transition To Dolutegravir-Based Treatment
- Conditions
- TeratogensCongenital AbnormalitiesNeural Tube Defects
- Registration Number
- NCT05883761
- Lead Sponsor
- Elizabeth Glaser Pediatric AIDS Foundation
- Brief Summary
The goal of this observational study is to assess the birth outcomes of HIV-positive women delivering in hospitals in Eswatini who are receiving dolutegravir (DTG) or other anti-retroviral (ARV) drug regimens. The main question the study aims to answer is, what is the proportion of neural tube defects among live and stillborn infants delivered by:
* HIV-positive women on DTG at conception
* HIV-negative women
* HIV-positive women on non-DTG ARV at conception
Participants will be interviewed for information on HIV testing and antiretroviral therapy history, other medical history of selected conditions (e.g., diabetes, malaria, TB) and potential birth defect exposures. Photographs will be taken of the infants. Data on mothers' pregnancy history, birth outcomes, and HIV and ARV information (as applicable) will be collected from patient records.
- Detailed Description
This is an observational study conducted at five high volume hospitals in Eswatini, in which birth defect and other data will be collected at the time of delivery (or hospital admission for miscarriages and medical abortions) for all women. The overall aim of this study is to evaluate the birth outcomes of HIV-positive women who are receiving DTG or other ARV drug regimens. The primary research objectives are to: 1) determine the proportion of neural tube defects among live and stillborn infants delivered by HIV-positive women on DTG at conception; 2) determine the proportion of neural tube defects among live and stillborn infants delivered by HIV-negative women; and 3) determine the proportion of neural tube defects among live and stillborn infants delivered by HIV-positive women on non-DTG ART at conception. Secondary objectives are to determine overall general prevalence of major external birth defects and other pregnancy outcomes and any associations with other factors (e.g., maternal age, gravida). Data on mothers' pregnancy history, birth outcomes, and HIV and ARV information (as applicable) are collected from patient charts, registers, reporting forms and databases for all women. Women of live or stillborn infants with birth defects are consented for interviews capturing detailed history and exposure data and photographs of newborns' birth defects. Data collection will be for approximately 24 months. Blinded interview data and photographs are reviewed by a medical geneticist for confirmatory defect diagnosis. We will describe rates and 95% confidence intervals (CI) for birth defects among infants by maternal HIV and ART status.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 50075
- women whose live or stillborn infant has birth defect as identified by a midwife or other clinician at the study hospital
- willing to provide informed consent
- unable to provide informed consent
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Proportion of neural tube defects (NTDs) among live and stillborn infants delivered by HIV-positive women on non-DTG ARV at conception 24 months Number of live and stillborn infants with NTDs divided by the total number of live and stillborn infants of HIV-positive women on non-DTG ARV at conception
Proportion of neural tube defects (NTDs) among live and stillborn infants delivered by HIV-positive women on DTG at conception. 24 months Number of live and stillborn infants with NTDs divided by the total number of live and stillborn infants of HIV-positive women on DTG at conception
Proportion of neural tube defects (NTDs) among live and stillborn infants delivered by HIV-negative women 24 months Number of live and stillborn infants with NTDs divided by the total number of live and stillborn infants of HIV-negative women
- Secondary Outcome Measures
Name Time Method Prevalence of major external birth defects among all live and stillborn infants regardless of maternal HIV or ART status. 24 months Number of live and stillborn infants with major external birth defects divided by the total number of live and stillborn infants among all women regardless of HIV or ART status
Proportion of other pregnancy outcomes 24 months Number of live and stillborn infants with low birthweight and pre-term delivery divided by the total number of live infants among women (overall and by HIV/ART status); number of stillborn infants among all pregnancies, including miscarriages
Trial Locations
- Locations (5)
Good Shepherd Hospital
🇸🇿Lubombo, Swaziland
Raleigh Fitkin Memorial Hospital
🇸🇿Manzini, Swaziland
Mankayane Government Hospital
🇸🇿Manzini, Swaziland
Mbabane Government Hospital
🇸🇿Mbabane, Swaziland
Hlathikhulu Hospital
🇸🇿Shiselweni, Swaziland